Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Julian W Sacre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Failure, Diabetic Angiopathies, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Sanofi, State Government of Victoria, Eli Lilly and Company.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Aims
Heart failure (HF) may develop in type 2 diabetes without prior cardiovascular disease (CVD). This study aimed to identify risk factors that distinguish CVD that presents first as a HF event versus CVD that presents first as an atherosclerotic event (ASCVD), among people with type 2 diabetes. Materials and methods ORIGIN and REWIND trial participants with type 2 diabetes but free of CVD ( N = 6175; 64 ± 7 years, 50.1% female) were followed for ~5.8 years for incident CVD presenting first as either a HF event (HF hospitalization or HF death), ASCVD (myocardial infarction, unstable angina, stroke, or revascularization), or other cardiovascular death. Multi‐state models characterised event‐specific associations of risk factors with each possible first CVD event.
Results
HF was the first event in 16.8% of 1024 incident CVD cases. Older age, higher BMI, and higher urine albumin:creatinine ratio were more strongly associated with CVD manifesting first as HF, rather than as ASCVD or other cardiovascular death. ASCVD as the first event (65.2% of cases) was more strongly associated with worse LDL‐cholesterol and HbA1c. These unique associations of risk factors with HF versus ASCVD translated to variable probabilities of HF as the first CVD event, depending on the clinical profile (32.0% for a profile enriched with HF‐specific risk factors versus 5.1% for a profile enriched with ASCVD‐specific risk factors).
Conclusions
CVD that presents first as a HF event is common in type 2 diabetes and its risk factors are distinct from those associated with CVD that presents first as an ASCVD event.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- Clinical and Translational Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
- INSERM Unit 1034, Biology of Cardiovascular Diseases, Bordeaux University Hospital, Bordeaux, France.
- Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
ORCID-Profile: Julian W Sacre, Kamel Mohammedi, Hertzel C Gerstein
Förderung
- Sanofi
- State Government of Victoria
- Eli Lilly and Company
- National Health and Medical Research Council
Zitieren
APA
Sacre, J. W., Lundegard, K., Mohammedi, K., Carstensen, B., Gerstein, H. C., & Shaw, J. E. (2026). Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70426
Vancouver
Sacre JW, Lundegard K, Mohammedi K, Carstensen B, Gerstein HC, Shaw JE. Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70426
BibTeX
@article{Sacre2026,
author = {Sacre, Julian W and Lundegard, Kristin and Mohammedi, Kamel and Carstensen, Bendix and Gerstein, Hertzel C and Shaw, Jonathan E},
title = {Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70426}
}
EUVIMED